MED Fundamental Analysis - MEDIFAST INC

Fundamental Rating

Overall MED gets a fundamental rating of 4 out of 10. We evaluated MED against 36 industry peers in the Personal Care Products industry. No worries on liquidiy or solvency for MED as it has an excellent financial health rating, but there are worries on the profitability. MED does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

MED had negative earnings in the past year.

MED had a positive operating cash flow in the past year.

Each year in the past 5 years MED has been profitable.

Each year in the past 5 years MED had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of 0.09%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

With a Return On Equity value of 0.12%, MED perfoms like the industry average, outperforming 58.33% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROIC	N/A

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MED has a Profit Margin of 0.06%. This is comparable to the rest of the industry: MED outperforms 50.00% of its industry peers.

In the last couple of years the Profit Margin of MED has declined.

MED's Operating Margin has declined in the last couple of years.

With a decent Gross Margin value of 72.44%, MED is doing good in the industry, outperforming 72.22% of the companies in the same industry.

In the last couple of years the Gross Margin of MED has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	0.06%
GM	72.44%

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MED does not have a ROIC to compare to the WACC, probably because it is not profitable.

MED has more shares outstanding than it did 1 year ago.

The number of shares outstanding for MED has been reduced compared to 5 years ago.

MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 4.53 indicates that MED is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 4.53, MED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.

There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	4.53

ROIC/WACCN/A

WACC8.82%

2.3 Liquidity

MED has a Current Ratio of 4.45. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.

MED's Current ratio of 4.45 is amongst the best of the industry. MED outperforms 83.33% of its industry peers.

MED has a Quick Ratio of 3.95. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.

MED has a Quick ratio of 3.95. This is amongst the best in the industry. MED outperforms 86.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.45
Quick Ratio	3.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.00%.

MED shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.59% yearly.

MED shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.29%.

Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.

EPS 1Y (TTM)-100%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

3.2 Future

MED is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -43.69% yearly.

The Revenue is expected to decrease by -23.25% on average over the next years. This is quite bad

EPS Next Y-78.11%

EPS Next 2Y-43.69%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

MED's Price/Free Cash Flow ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	194.28
EV/EBITDA	-15.75

4.3 Compensation for Growth

MED's earnings are expected to decrease with -43.69% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-43.69%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MED has a Yearly Dividend Yield of 9.97%, which is a nice return.

MED's Dividend Yield is rather good when compared to the industry average which is at 2.04. MED pays more dividend than 97.22% of the companies in the same industry.

MED's Dividend Yield is rather good when compared to the S&P500 average which is at 1.90.

		Industry Rank	Sector Rank
Dividend Yield	9.97%

5.2 History

The dividend of MED decreases each year by -53.42%.

MED has been paying a dividend for over 5 years, so it has already some track record.

Dividend Growth(5Y)-53.42%

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.

The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.

DP78.63%

EPS Next 2Y-43.69%

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDIFAST INC

NYSE:MED (1/9/2026, 8:04:00 PM)

After market: 11.42 0 (0%)

11.42

+0.39 (+3.54%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)11-03 2025-11-03/amc

Earnings (Next)02-16 2026-02-16/amc

Inst Owners84.91%

Inst Owner Change0%

Ins Owners3.3%

Ins Owner Change0%

Market Cap125.51M

Revenue(TTM)429.69M

Net Income(TTM)248.00K

Analysts46.67

Price Target15.3 (33.98%)

Short Float %18.76%

Short Ratio8.49

Dividend

		Industry Rank	Sector Rank
Dividend Yield	9.97%

Yearly Dividend0.07

Dividend Growth(5Y)-53.42%

DP78.63%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)122.85%

Min EPS beat(2)46.69%

Max EPS beat(2)199.01%

EPS beat(4)4

Avg EPS beat(4)116.81%

Min EPS beat(4)46.69%

Max EPS beat(4)199.01%

EPS beat(8)6

Avg EPS beat(8)95.8%

EPS beat(12)10

Avg EPS beat(12)87.61%

EPS beat(16)13

Avg EPS beat(16)70.85%

Revenue beat(2)2

Avg Revenue beat(2)7.01%

Min Revenue beat(2)5.26%

Max Revenue beat(2)8.75%

Revenue beat(4)4

Avg Revenue beat(4)5.3%

Min Revenue beat(4)3.13%

Max Revenue beat(4)8.75%

Revenue beat(8)7

Avg Revenue beat(8)3.21%

Revenue beat(12)11

Avg Revenue beat(12)3.67%

Revenue beat(16)14

Avg Revenue beat(16)3.57%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-82.22%

EPS NY rev (1m)0%

EPS NY rev (3m)147.31%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.29
P/FCF	194.28
P/OCF	17.45
P/B	0.58
P/tB	0.58
EV/EBITDA	-15.75

EPS(TTM)0

EYN/A

EPS(NY)-0.13

Fwd EYN/A

FCF(TTM)0.06

FCFY0.51%

OCF(TTM)0.65

OCFY5.73%

SpS39.1

BVpS19.54

TBVpS19.54

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	0.06%
GM	72.44%
FCFM	0.15%

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)57.45%

ROCE(5y)70.54%

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

F-Score5

Asset Turnover1.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	46.9%
Cap/Sales	1.52%
Interest Coverage	N/A
Cash Conversion	89.73%
Profit Quality	260.48%
Current Ratio	4.45
Quick Ratio	3.95
Altman-Z	4.53

F-Score5

WACC8.82%

ROIC/WACCN/A

Cap/Depr(3y)86.65%

Cap/Depr(5y)168.74%

Cap/Sales(3y)0.96%

Cap/Sales(5y)1.15%

Profit Quality(3y)359.98%

Profit Quality(5y)250.42%

High Growth Momentum

Growth

EPS 1Y (TTM)-100%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

EPS Next Y-78.11%

EPS Next 2Y-43.69%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-120.14%

EBIT growth 3Y-55.18%

EBIT growth 5Y-26.54%

EBIT Next Year-105.07%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-99.63%

FCF growth 3Y-34.4%

FCF growth 5Y-25.51%

OCF growth 1Y-96.19%

OCF growth 3Y-36.26%

OCF growth 5Y-21.91%

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.

Can you provide the valuation status for MEDIFAST INC?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.

Can you provide the profitability details for MEDIFAST INC?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.

Can you provide the financial health for MED stock?

The financial health rating of MEDIFAST INC (MED) is 9 / 10.

MEDIFAST INC (MED) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

Can you provide the valuation status for MEDIFAST INC?

Can you provide the profitability details for MEDIFAST INC?

Can you provide the financial health for MED stock?